Pharmacometrics in pregnancy: An unmet need

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 53-69

  Ke, Alice Ban ^a   Rostami Hodjegan, Amin ^b,c   Zhao, Ping ^d   Unadkat, Jashvant D ^e  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CERTARA UK LIMITED   (United Kingdom)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP; Modeling; PBPK; POP PK; Simulation

Indexed keywords

ALBUMIN; AMOXICILLIN; CAFFEINE; CREATININE; DEXTROMETHORPHAN; DIGOXIN; GLIBENCLAMIDE; INDINAVIR; LABETALOL; LAMOTRIGINE; METFORMIN; METHADONE; METOPROLOL; MIDAZOLAM; NICOTINE; PHENYTOIN; PROGUANIL; THEOPHYLLINE; ZIDOVUDINE;

ALBUMIN BLOOD LEVEL; BODY WEIGHT; CLINICAL STUDY; CREATININE CLEARANCE; DATA ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ERYTHROCYTE VOLUME; FAT MASS; FEMALE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMATOCRIT; HUMAN; KIDNEY PLASMA FLOW; LIVER BLOOD FLOW; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; MODEL; PLASMA VOLUME; POPULATION RESEARCH; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; STOMACH MOTILITY; STOMACH PH; STUDY DESIGN; TOTAL BODY WATER; UTERUS BLOOD FLOW;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREGNANCY;

EID: 84891842465     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-140009     Document Type: Review

References (57)

1. Glover DD, Amonkar M, Rybeck BF, Tracy TS. 2003. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am. J. Obstet. Gynecol. 188:1039-45
2. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, et al. 2004. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol. 191:398-407
3. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, et al. 2006. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol. Drug Saf. 15:546-54
4. Endicott S, Haas DM. 2012. The current state of therapeutic drug trials in pregnancy. Clin. Pharmacol. Ther. 92:149-50
5. Anger GJ, Piquette-Miller M. 2008. Pharmacokinetic studies in pregnant women. Clin. Pharmacol. Ther. 83:184-87
6. US Dep. Health Hum. Serv., Food Drug Admin., Cent. Drug Eval. Res. (CDER). 2004. Guidance for industry: Pharmacokinetics in pregnancy-study design, data analysis, and impact on dosing and labeling. US Food Drug Admin., Rockville, Md. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072133.pdf
7. rd American conference on pharmacometrics. Br. J. Clin. Pharmacol. 74:932-39
8. Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, et al. 2007. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 51:783-86
9. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, et al. 2009. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin. Pharmacol. Ther. 85:607-14
10. Etwel F, Hutson J, Madadi P, Gareri J, Koren G. 2014. Fetal and perinatal exposure to drugs and chemicals: novel biomarkers of risk. Annu. Rev. Pharmacol. Toxicol. 54:295-315
11. Panel Antiretrovir. Guidel. Adults Adolesc. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDS info, US Dep. Health Hum. Serv., Rockville, Md. http://www.aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf
12. Mirochnick M, Clarke D. 2011. Oseltamivir pharmacokinetics in pregnancy: a commentary. Am. J. Obstet. Gynecol. 204:S94-95
13. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. 2012. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 51:365-96
14. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, et al. 2008. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84:248-53
15. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, et al. 2008. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin. Trials 9:115-25
16. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44:989-1008
17. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. 1994. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 35:122-30
18. Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377-90
19. Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, et al. 2009. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 85:60-64
20. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, et al. 2010. Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 38:833-40
21. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. 2009. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab. Dispos. 37:386-90
22. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, et al. 2007. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin. Pharmacol. Ther. 81:547-56
23. Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, et al. 2010. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob. Agents Chemother. 54:360-66
24. Mirochnick M, Best BM, Clarke DF. 2010. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin. Perinatol. 37:907-27, xi
25. Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A, Milligan PA. 2009. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm. Stat. 8:186-202
26. Fischer JH, Sarto GE, Habibi M, Kilpatrick SJ, Tuomala RE, et al. 2012. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. Antimicrob. Agents Chemother. 56:715-24
27. Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-Part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacomet. Syst. Pharmacol. 2:e38
28. Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, et al. 2012. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob. Agents Chemother. 56:857-62
29. McGready R, White NJ, Nosten F. 2011. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. Br. J. Obstet. Gynaecol. 118:123-35
30. Rowland M, Peck C, Tucker G. 2011. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51:45-73
31. Jamei M, Dickinson GL, Rostami-Hodjegan A. 2009. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs. 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24:53-75
32. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, et al. 2011. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89:259-67
33. Lu G, Abduljalil K, Jamei M, Johnson TN, Soltani H, Rostami-Hodjegan A. 2012. Physiologically-based pharmacokinetic (PBPK)models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. Curr. Drug Metab. 13:695-720
34. Andrew MA, Hebert MF, Vicini P. 2008. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2008:5454-57
35. Lu G, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. 2012. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6, and CYP3A4. Br. J. Clin. Pharmacol. 74:873-85
36. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. 2012. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT Pharmacomet. Syst. Pharmacol. 1:e3. doi: 10.1038/psp.2012.2
37. Ke AB, Nallani S, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD. 2013. A PBPK model to predict disposition of P450 2D6 and P450 1A2 metabolized drugs in pregnant women. Drug Metab. Dispos. 41(4):801-13
38. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. 2013. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br. J. Clin. Pharmacol. In press. doi: 10.1111/bcp.12207
39. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD. 2010. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab. Dispos. 38:241-48
40. Quinney SK, Mohamed AN, MFH, Haas DM, Clark S, et al. 2012. A semi-mechanisticmetabolismmodel of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT Pharmacomet. Syst. Pharmacol. 1:e2. doi: 10.1038/psp.2012.5
41. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. 2000. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:209-34
42. Rothberger S, Carr D, Brateng D, Hebert M, Easterling TR. 2010. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am. J. Hypertens. 23: 1234-40
43. Østensen M, Villiger PM, Förger F. 2012. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun. Rev. 11:A437-46
44. Papageorgiou I, Grepper S, Unadkat JD. 2013. Induction of hepatic CYP3A enzymes by pregnancyrelated hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab. Dispos. 41:281-90
45. 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J. Nucl. Med. 54:437-46
46. Prasad B, Lai Y, Lin Y, Unadkat JD. 2013. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J. Pharm. Sci. 102:787-93
47. Leong R, Vieira MLT, Zhao P, Mulugeta Y, Lee CS, et al. 2012. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91:926-31
48. Tracy TS, Venkataramanan R, Glover DD, Caritis SN. 2005. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol. 192:633-39
49. Gardner MJ, Schatz M, Cousins L, Zeiger R, Middleton E, Jusko WJ. 1987. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur. J. Clin. Pharmacol. 32:289-95
50. Dempsey D, Jacob P III, Benowitz NL. 2002. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J. Pharmacol. Exp. Ther. 301:594-98
51. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. 1994. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 35:131-35
52. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, et al. 2003. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur. J. Clin. Pharmacol. 59:545-52
53. Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A. 1985. Pregnancy-induced increase in metoprolol metabolism. Clin. Pharmacol. Ther. 37:688-92
54. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. 1985. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J. Pharmacol. Exp. Ther. 233:1-6
55. Hardman J, Endres L, Fischer P, Fischer J. 2005. Pharmacokinetics of labetalol in pregnancy. Pharmacotherapy 25:1493
56. Retrovir® (zidovudine) Tablets, Capsules, and Syrup [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2011. http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/019655s052,019910s039,020518s022lbl.pdf
57. Gerdin E, Salmonson T, Lindberg B, Rane A. 1990. Maternal kinetics of morphine during labour. J. Perinat. Med. 18:479-87